Final Project - Elevator Pitch Create a powerpoint

1

Supply Market Analysis of the Healthcare and Pharmaceutical Cold Chain Logistics Industry

Student Name

National University

SCM 640 Distribution Management

Instructor Name

Date

Executive Summary

The cold chain logistics of healthcare and pharmaceuticals are a high-risk transportation market since the quality of the product is determined by tested temperature control, recorded handling, and prompt response to excursions. This updated supply market analysis considers the market of healthcare cold chain third-party logistics, focusing on refrigerated, frozen, and controlled ambient transportation and distribution of vaccines, biologics, specialty drugs, clinical trial materials, and cell and gene therapies. The global healthcare cold chain third-party logistics market is projected to grow to $45.8 billion in 2025, and the growth is projected to rise to 83.4 billion by 2033 at a compound annual growth rate of 7.7% (Grand View Research, 2026). But this is a figure that shows an increase in market demand, rather than a direct transportation rate projection.

The best result is that reliability, compliance, visibility, and contingency capacity are more significant than the lowest quoted price. The largest service segment of 42.9% of market revenue is refrigerated transportation, which justifies the conclusion that transportation capacity is the primary cost and service risk in this market (Grand View Research, 2026). All of McKesson, UPS Healthcare, and DHL Life Sciences and Healthcare can be considered key players, but they do not fulfill the same functions. McKesson is best at United States pharmaceutical distribution and integration of inventory, UPS Healthcare is best at technology-enabled regional and global healthcare transportation, and DHL is best at international life sciences logistics and specialized clinical supply networks. The sourcing strategy suggested is a selective multisupplier approach: DHL should be used for global and specialty lanes, UPS should be used for domestic and regional lanes with good visibility, and McKesson should be used for the pharmaceutical distribution in the United States. The organization must shun off suppliers who are not capable of demonstrating verified infrastructure, real-time monitoring, excursion procedures, regulatory expertise, and audited quality arrangements.

Introduction

Transportation is what links manufacturers, wholesalers, providers, and patients, and thus has a direct impact on the reliability of service, availability of inventory, and the cost of the entire supply chain. According to Novack et al. (2019), transportation choices influence the customer service and inventory policy since the speed of movement, reliability, and cost are the factors that define the amount of inventory a company needs to maintain and the speed at which it can respond to demand. The relational aspect of this is more significant in medical care since time and temperature-sensitive products may be rendered useless when handlers do not meet the storage and transportation needs. The CDC cautions that poor vaccine storage may decrease or even kill its efficacy and may cause insufficient immunity among the recipients (Centers for Disease Control and Prevention, 2024). Hence, cold chain logistics is not merely a freight purchase decision, but a patient safety and risk management decision.

This report discusses cold chain transportation and distribution of healthcare and pharmaceuticals in the third-party logistics market across the world. The market size, market characteristics, demand trends, supply trends, cost intelligence, major developments, key player financial health, SWOT findings, Porter's Five Forces, price and rate outlook, and sourcing recommendations are analyzed. The three examined key players are McKesson, UPS Healthcare, and DHL Life Sciences and Healthcare. Their selection was due to the fact that McKesson offers bulk distribution of pharmaceuticals, whereas UPS and DHL offer specialized transportation, warehousing, and international logistics services to healthcare clients.

Market Overview

The cold chain market in healthcare is a large, regulated, and specialized market. Grand View Research (2026) projects the market of cold chain third-party logistics in the global healthcare market to reach 45.8 billion in 2025, and North America is the largest market with 38.2 percent of revenue. According to the same source, the Asia Pacific is the most rapidly expanding area between 2026 and 2033, meaning that sourcing teams should be global, not have one domestic transportation solution. The market is not a pure commodity market since the buyers are charged with the validated processes, lane qualification, monitoring, documentation, packaging, and the ability to take corrective measures, instead of the mere point-to-point freight movement.

The market is appealing and challenging to operate due to several demand drivers. In 2025, biopharmaceuticals were the largest product segment, and the development of specialty pharmaceuticals enhanced the quantity of shipments that needed refrigeration, frozen storage, controlled ambient networks, or cryogenic management (Grand View Research, 2026). Vaccines that need refrigerator temperatures should be kept in a general range of 2 C to 8 C, with product inserts and special instructions potentially having different ranges with certain products (Centers for Disease Control and Prevention, 2024). As a result, buyers need to filter suppliers based on product profile and lane risk rather than presume that a single cold chain service can handle all healthcare shipments.

There is also a high regulatory and quality dimension in the market. According to WHO recommendations, medical products are susceptible to supply chain risks in the process of purchasing, storing, repackaging, transportation, and distribution, and therefore storage and distribution activities should safeguard product quality throughout the supply chain (World Health Organization, 2020). Another point that IATA makes is that healthcare and life science products are perishable and time and temperature-sensitive, and that shippers must have up-to-date carrier rules, government rules, packaging requirements, and documentation practices prior to shipment (International Air Transport Association, n.d.). Such requirements increase barriers to entry and provide benefits to providers whose systems are of good quality, whose staff are trained, whose assets are validated, and whose data collection is reliable.

Industry Trends and Key Developments

There are four trends in the transportation and distribution decisions in the industry. First, biologics and specialty drugs make services more sensitive to the service since the value of the products is high, and the acceptable temperature ranges can be low. This tendency moves procurement out of spot buying to the contracted partners with quality agreements, monitoring, and lane validation.

Second, digital monitoring is no longer an optional visibility but a fundamental risk control. According to Lam and Tang (2023), cold chain freight forwarding poses operational difficulties when the shipment status is checked manually daily and split information, which is why digital transformation can minimize the number of errors and enhance responsiveness. Zeng et al. (2024) also demonstrate that blockchain, Internet of Things devices, and multisensor data can enhance the medicine logistics traceability and quality evaluation.

Third, cell and gene therapies are putting pressure on the provision of specialized clinical logistics. In 2025, DHL purchased CRYOPDP to enhance specialty pharma logistics to clinical trials, biopharma, and cell and gene therapies, and CRYOPDP made over 600,000 shipments annually in over 135 countries prior to the acquisition (DHL Group, 2025). This acquisition exemplifies the use of large logistics companies to grow by acquiring specialized capabilities instead of developing all capabilities in-house.

Fourth, sustainability and energy efficiency are also becoming important when making equipment decisions, network design, packaging selection, and rate discussions. Nonetheless, sustainability does not exclude the concept of redundancy since healthcare cold chain purchasers need to ensure the safety of the product quality in the case of weather conditions, customs delays, airport congestion, and power outages.

Cost Intelligence

The original cost breakdown cannot be considered as a sourced industry fact since no reliable source identified the specific 35%, 20%, 15%, 10%, 10%, and 10% allocation. An enhanced cost model will isolate market revenue evidence and supplier cost drivers. According to Grand View Research (2026), transportation is the biggest segment of healthcare cold chain third-party logistics revenue in 2025 (42.9%). This result confirms a transportation-oriented benchmark, but not that transportation is 42.9 percent of all the internal costs of all the suppliers or all the invoices of all customers.

The price should be fair and reasonable, considering the entire service bundle. Validated storage rooms, qualified vehicles, temperature mapping, information technology platforms, quality audits, staff training, compliance documentation, and redundant equipment are examples of fixed cost drivers. Variable cost drivers are mode, lane distance, fuel, driver labor, type of packaging, type of sensor, value of payload, complexity of customs, delivery window, product temperature range, and emergency recovery requirements. A typical parcel rate will not be able to benchmark a specialty pharmaceutical lane since the buyer is paying to have the temperature guaranteed and the control recorded. Consequently, procurement must solicit itemized bids that distinguish transport, packaging, monitoring, warehouse handling, documentation, customs support, and contingency services.

Analysis of Key Players

McKesson is also an integrator of pharmaceutical distribution and supply chain, as opposed to a traditional transportation carrier. Its significant strength is the scale of distribution in the United States, relations with customers, coordination of inventory, and integration of pharmacy services. In fiscal 2026, McKesson recorded a revenue of 403.4 billion and a net income that is attributable to the company of 4.8 billion, with its growth in revenue driven mainly by its North American Pharmaceutical segment and its Oncology and Multispecialty segment (McKesson Corporation, 2026). This scale provides McKesson with investment potential and transforms it into a powerful partner in case the purchasing requirement is connected with drug distribution, replenishment, inventory visibility, and access to healthcare channels. But its poor gross margin picture requires that the buyer consider service charges, distribution conditions, and channel fit.

UPS Healthcare is a dedicated logistics company that is a part of a greater transportation company. UPS posted 2025 revenue of 88.7 billion, operating profit of 7.9 billion, and operating margin of 8.9 percent, which signifies a robust cash-generating platform to invest in the network (United Parcel Service, 2026). UPS provides value in which consumers require dependable small package, air, ground, healthcare warehousing, visibility, and temperature-controlled transportation over established lanes. Its vulnerability is that it is exposed widely to labor, fuel, and network utilization pressures. However, a healthcare buyer can mitigate risk through UPS as a validated regional network and technology-enabled transport execution.

DHL Life Sciences and Healthcare offers the best international logistics match among the three vendors. DHL Group reported revenue of 2025 of EU82.9billion, EBIT of EU6.1billion, return on sales of 7.4, and free cash flow of EU2.3billion (DHL Group, 2026). In 2024, DHL also registered over 5 billion in global revenue in its Life Sciences and Healthcare division, and its CRYOPDP takeover boosted its specialty courier service in clinical trials and sophisticated treatment (DHL Group, 2025). The most valuable sourcing assets that DHL has are its global network, multimodal international capability, and specialty life sciences footprint. Its primary threat is operational complexity across geopolitical environments, countries, and customs regimes.

Financial Health Evaluation

The financial health rating employs four factors: scale, profitability, cash generation, and strategic fit with healthcare cold chain needs. Very healthy implies that the provider has a large revenue, a positive profit, the presence of cash generation, and a good fit to the considered cold chain use case. Healthy implies that the provider is enjoying good profit and cash generation, as well as significant exposure to cyclical transportation or international complexity. According to these criteria, McKesson is quite healthy as a pharmaceutical distribution, whereas UPS and DHL are healthy as logistics and transportation partners.

The summary of the financial evidence follows. McKesson is the biggest by scale, with a revenue of $403.4billion and net income of $4.8 billion in the fiscal year 2026, which can be attributed to McKesson (McKesson Corporation, 2026). UPS is highly profitable in the transportation sector, as the company will have 88.7 billion in 2025 revenue and an operating margin of 8.9 percent (United Parcel Service, 2026). DHL demonstrates a wide international stability, having a revenue of €82.9 billion in 2025 and an EBIT of €6.1 billion (DHL Group, 2026). These numbers are not reflective of the cold chain revenue of individual firms, and hence the report uses them as an indicator of corporate investment potential, but no longer as cold chain market share.

Provider	Key evidence	Rating	Sourcing meaning
McKesson	$403.4 billion revenue and $4.8 billion net income	Very healthy	Best for the United States pharmaceutical distribution
UPS Healthcare	$88.7 billion revenue and 8.9% operating margin	Healthy	Best for validated transport and visibility
DHL Life Sciences and Healthcare	€82.9 billion revenue and €6.1 billion EBIT	Healthy	Best for global and specialty life sciences lanes

SWOT Analysis

The strengths that McKesson has are the scale of its pharmaceuticals, inventory, relationships with healthcare, and distribution channels. These are the strengths that it can leverage to meet its strategic objective of meeting complex pharmaceutical demand, with specialty and oncology distribution being the key areas. Its weaknesses are that it relies on the economics of pharmaceutical distribution, it is exposed to regulations, and it cannot be directly compared to logistics carriers. It has chances such as specialty drug development and more channel integration. Some of its threats are pricing pressure, reimbursement changes, and compliance risk. McKesson should therefore be used in cases where the buyer requires distribution integration, but not in cases where a global cold chain carrier is required on international transportation lanes.

The strengths of UPS Healthcare are the density of transportation, technology platforms, healthcare warehousing, and the efficient execution of the parcel and freight networks. These strengths suit the customers requiring domestic and regional temperature-regulated transportation, responsiveness, and visibility of the shipment levels. Its vulnerabilities are exposure to fuel, labor, capacity utilization, and transportation rate pressure. Its opportunities are biologics, clinical trial logistics, and home delivery of healthcare. Threats to it are competition in the services provided and macroeconomic volatility in shipments. Thus, UPS must be given priority in lanes that have been verified and where visibility and reliability of delivery are most important.

DHL has such advantages as global presence, experience in life sciences, air and forwarding, and specialized clinical logistics growth. It has weaknesses such as global complexity, customs exposure, and geopolitical risk. It has opportunities such as Asia Pacific healthcare growth, advanced therapy logistics, and integrated global health logistics. Its risks are border disruptions, variable regulation, and competition with other international providers. Hence, international lanes, clinical trial movements, and advanced therapy networks, which demand cross-border coordination, should be given precedence over DH.

Porter’s Five Forces

There is intense competition among the leading logistics providers, pharmaceutical distributors, forwarders, and specialty couriers based on reliability, proven infrastructure, technology, and scope of services. Price is important, yet buyers cannot make decisions based solely on price since the loss of products and patient injuries can be higher than the savings on transportation. The threat of new entrants is low since the entrants must have tested facilities, refrigerated equipment, approved packaging partners, trained employees, quality systems, information technology, and regulatory expertise. WHO and IATA guidelines affirm that the storage and distribution must be compliant with documented practices and shipment controls, which increases the entry cost (International Air Transport Association, n.d.; World Health Organization, 2020).

The power of suppliers is moderate due to the specialization of inputs such as refrigeration equipment, packaging, sensors, dry ice, vehicles, and qualified air capacity. The buyer power is also high in large pharmaceutical manufacturers, health systems, and distributors that are able to negotiate the contract terms as they are large purchasers and can award several lanes. There is a low threat of substitutes as sensitive medical products cannot pass through normal freight networks without proven conditions. The sourcing implication is obvious: competitive bidding should be employed by buyers, but suppliers must be prequalified based on their quality capability prior to price comparison.

Price and Rate Outlook

The following 12 months ought to reflect a moderate upward pressure instead of an equal 8% to 12% rise in transportation rate. The 8% to 12% claim of the past must be eliminated since the market evidence available indicates that the market revenue will grow at 7.7 percent per annum between 2026 and 2033, not the growth in customer freight bills (Grand View Research, 2026). The increase in demand can justify the increased utilization and pricing power, yet the rates are also subject to fuel, labor, mode, lane balance, capacity, packaging availability, regulatory burden, complexity of customs, and level of service.

The fair price benchmark must thus be in the language of scenarios. When labor and fuel are high, refrigerated parcel and domestic lanes are expected to be under moderate pressure. The international air and clinical trial lanes should be more pressure-driven as they require further documentation, qualified packaging, coordination with customs, and contingency planning. The costs of warehouse and packaging can increase as customers demand greater validation, monitoring, and sustainability. Automation can minimize handling errors and operating costs in the long run, but these savings will not completely pay off the redundancy and compliance costs.

Sourcing Recommendation

The suggested approach is a selective multisupplier model, as opposed to a single winner model. One supplier poses the risk of dependence and does not take into account that the three providers possess various business models. The buyer ought to use McKesson to distribute pharmaceuticals in the United States, provide support to pharmacies, manage inventory, and provide replenishment services. The buyer is supposed to contract with UPS Healthcare to offer proven domestic and regional transportation, temperature-controlled parcel, healthcare warehousing, and visibility-intensive lanes. DHL Life Sciences and Healthcare should be hired by the buyer to conduct worldwide transportation, clinical trial logistics, cross-border specialty shipments, and advanced therapy lanes. This structure aligns every supplier with the use case in which it has the most evidence.

The scorecard below supports the recommendation. DHL is rated the best in terms of global and specialty life sciences logistics due to the international network and CRYOPDP specialty acquisition (DHL Group, 2025). The best score is given to UPS in terms of technology-enabled transportation execution in known lanes due to its extensive network and profitable operating performance (United Parcel Service, 2026). United States pharmaceutical distribution is rated highest at McKesson since the scale of revenues and segment performance evidence that McKesson has deep distribution capabilities (McKesson Corporation, 2026). The company must not deal with suppliers who fail to offer proven storage and transportation equipment, documented temperature mapping, real-time monitoring, excursion reporting, trained staff, audit access, quality contracts, insurance documentation, and contingency recovery plans. When the team is unable to confirm these requirements, the supplier must be disqualified, even in cases where it has a lower price.

Master service agreements with lane-level quality appendices should be negotiated by the buyer. The obligations encompassed in every contract are the temperature ranges, ownership of data, excursion response time, packaging, responsibility of customs documentation, audit rights, schedule of corrective action, and performance metrics. The best measures are on-time full delivery, rate of temperature excursion, accuracy of documentation, uptime of shipment visibility, timely closure of corrective actions, rate of claims, and emergency recovery performance. The sourcing model safeguards the quality of services and maintains competition since the buyer is able to switch lanes depending on performance.

Criteria	McKesson	UPS Healthcare	DHL Life Sciences and Healthcare
Cold chain capability	Strong distribution capability	Strong transport capability	Very strong global capability
Geographic reach	Strong United States reach	Strong regional and global reach	Very strong global reach
Visibility and quality data	Strong inventory visibility	Strong shipment visibility	Strong international visibility
Financial health	Very healthy	Healthy	Healthy
Best use case	Drug distribution integration	Validated transportation	Global specialty logistics

Conclusion

As the analysis reveals, healthcare and pharmaceutical cold chain logistics are a niche supply market in which quality assurance and transportation delivery directly impact patient safety. The market is growing because biologics, specialty drugs, vaccines, and advanced therapies require reliable temperature-controlled distribution. Simultaneously, regulatory demands, technology investment, energy expenditure, labor expense, and global disruption risk complicate the market compared to normal freight. Thus, unsupported cost percentages and unsupported growth claims should not be used by buyers in developing a sourcing decision.

The sourcing decision should involve all three players, each with different needs. McKesson is to support the United States pharmaceutical distribution and inventory integration, UPS Healthcare is to support the validated transportation and visibility-intensive lanes, and DHL Life Sciences and Healthcare is to support the global and specialty life sciences logistics. Suppliers with unverified infrastructure, monitoring, regulatory, and contingency procedures should be avoided. The buyer has quality control, financial stability, operational flexibility, and defensible supplier selection with this strategy.

References

Centers for Disease Control and Prevention. (2024, June 18). Storage and handling of immunobiologics. https://www.cdc.gov/vaccines/hcp/imz-best-practices/storage-handling-immunobiologics.html

DHL Group. (2025, March 31). DHL Group acquires CRYOPDP from Cryoport to strengthen DHL Health Logistics. https://group.dhl.com/en/media-relations/press-releases/2025/dhl-group-acquires-cryopdp-from-cryoport-to-strengthen-dhl-health-logistics.html

DHL Group. (2026). Key financial figures: DHL Group 2025 annual report. https://reporting-hub.group.dhl.com/2025-fy/en/the-company/key-figures/

Grand View Research. (2026). Healthcare cold chain third-party logistics market size, share, and trends analysis report, 2026 to 2033. https://www.grandviewresearch.com/industry-analysis/healthcare-cold-chain-third-party-logistics-market-report

International Air Transport Association. (n.d.). Temperature Control Regulations. https://www.iata.org/en/publications/manuals/temperature-control-regulations/

Lam, H. Y., & Tang, V. (2023). Digital transformation for cold chain management in the freight forwarding industry.  International Journal of Engineering Business Management,  15, 18479790231160857. https://doi.org/10.1177/18479790231160857

McKesson Corporation. (2026). Form 10 K annual report for the fiscal year ended March 31, 2026. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/927653/000092765326000069/mck-20260331.htm

Novack, R. A., Gibson, B. J., Suzuki, Y., & Coyle, J. J. (2019). Transportation: A global supply chain perspective (9th ed.). Cengage Learning.

United Parcel Service, Inc. (2026). 2025 annual report on Form 10 K. https://investors.ups.com/sec-filings/all-sec-filings/content/0001628280-26-008432/ups-20251231.htm

World Health Organization. (2020). TRS 1025 Annex 7: Good storage and distribution practices for medical products. https://www.who.int/publications/m/item/trs-1025-annex-7

Zeng, W., Wang, Y., Liang, K., Li, J., & Niu, X. (2024). Advancing emergency supplies management: a blockchain‐based traceability system for cold‐chain medicine logistics.  Advanced Theory and Simulations,  7(4), 2300704. https://doi.org/10.1002/adts.202300704